Blood Podcast: October 14, 2025 Episode Summary

Overview

This episode of the Blood Podcast, hosted by the American Society of Hematology, features summaries and insights from two recently published studies in the journal Blood. The episode covers:

• A phase 3 trial comparing busulfan-melphalan (BUMEL) versus melphalan alone (MEL200) as conditioning therapy in newly diagnosed, transplant-eligible multiple myeloma.
• The use of spatial transcriptomics to reveal the complex, three-dimensional cellular interactions within the multiple myeloma bone marrow microenvironment.

1. Busulfan-melphalan Conditioning vs. Melphalan Alone in Multiple Myeloma

Study reference: High dose Busulfan Melphalan versus Melphalan and reinforced VRD in newly diagnosed multiple myeloma: A phase three GEM trial by Juan Jose La Huerta et al.

Background & Rationale

• [00:32]
  • Melphalan 200 mg/m² (MEL200) has been the standard transplant conditioning for over 30 years.
  • Busulfan-melphalan (BUMEL) combination showed potential effectiveness in retrospective studies, but lacked prospective head-to-head data.

Study Design & Methodology

• [01:06]
  • GEM12 phase 3 study compared BUMEL vs. MEL200 in the context of reinforced VRD (bortezomib, lenalidomide, dexamethasone) induction and consolidation.
  • 458 patients from 69 sites in Spain; 23% stage 3, 20% high-risk cytogenetics.
  • Randomization: After 6 cycles of reinforced VRD induction, patients received either MEL200 or BUMEL as transplant conditioning.
  • Post-transplant: Two further VRD cycles as consolidation.
  • [02:08]
    • GEM14 sub-study: Maintenance therapy comparison (lenalidomide+dexamethasone ± ixazomib).

Key Results & Outcomes

• [02:26]
  • Progression-Free Survival (PFS):
    • Median PFS overall: 78 months (9-year PFS: 41.4%).
    • BUMEL: 89.0 months vs. MEL200: 73.1 months (numerical difference, not statistically significant).
  • Overall Survival (OS):
    • 9-year OS: 66% for all patients.
  • Safety: Slightly more grade 2–4 infections with BUMEL.
  • Minimal Residual Disease (MRD) Negativity:
    • Statistically higher in BUMEL (68%) vs MEL200 (58%).
  • Subgroup Analyses:
    • PFS advantage for BUMEL in stage 2/3 disease and high-risk cytogenetics (e.g., t(14;16), del1p).
    • Stage 1 patients did better with MEL200.

Expert Commentary & Implications

• [03:30]
  • Donna Reese (Princess Margaret Cancer Centre, Canada):
    • “These results suggest a potential role for BUMEL in selected high-risk patients who also receive reinforced VRD in settings where CD38 inhibitors are unavailable.” [03:38]
    • Warned that ongoing improvements in induction/consolidation regimens may limit clear, broad indications for BUMEL in the future.

2. Spatial Transcriptomics of Multiple Myeloma Bone Marrow

Study reference: Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics by Raymond K.H. Yip et al.

Study Motivation & Technique

• [04:16]
  • Multiple myeloma develops with complex subclonal evolution, influenced by the bone marrow microenvironment.
  • Traditional single-cell RNA studies lose spatial information as they utilize digested tissue.
  • This study used spatial transcriptomics to preserve and analyze the three-dimensional (3D) bone marrow architecture.

Methodology

• [04:47]
  • Developed new bone marrow preservation methods compatible with the commercial spatial transcriptomics platform.
  • Analyzed 21 patient samples:
    • 7 with premalignant disease (MGUS or smoldering myeloma)
    • 10 with newly diagnosed multiple myeloma
    • 4 controls (lymphoma patients without marrow involvement)
  • Confirmed cell identity using cluster analysis and established markers. Detected thousands of gene transcripts per cell.

Findings

• [05:18]
  • Cell Composition:
    • Premalignant and control marrows: similar cell type proportions; slight plasma cell expansion in MGUS/smoldering myeloma.
    • Multiple myeloma: Massive plasma cell expansion, reduction of other blood cell types.
• [06:16]
  • Plasma Cell Diversity:
    • Controls/premalignants: 2 major plasma cell subtypes.
    • Myeloma: Up to 14 unique subtypes per patient, often showing functions like inflammation or proliferation.
  • Spatial Patterns:
    • Some patients had a single plasma cell type spread throughout marrow.
    • Others had multiple spatially-restricted plasma cell subtypes, each with unique gene signatures.
    • Examples: Subclones with translocation t(4;14) showed FGFR3 overexpression in specific bone marrow regions.
• [07:30]
  • Stromal Microenvironment:
    • Found expected stromal types (endothelial, mesenchymal, osteoblasts, etc.), but only subtle differences between controls and myeloma.
    • Key finding: Diverse “neighborhoods” formed by spatial proximity of plasma cell subtypes and local stromal cells.
    • “There isn’t a universal microenvironment supporting all malignant plasma cell clones. Rather, there are multiple niche environments that vary by patient and across the three-dimensional marrow architecture.” [08:10]

Expert Commentary & Broader Impact

• [08:27]
  • Leo Raske (University Hospital Wurzburg) & Niels Weinhold (Heidelberg University):
    • Praised the feasibility of spatial transcriptomics for examining tumor microenvironments in myeloma.
    • “This architecture is only one feature of the intra- and inter-patient variability that must be understood to advance our understanding of multiple myeloma.” [08:44]

Notable Quotes & Memorable Moments

• Donna Reese [03:38]:
  “These results suggest a potential role for BUMEL in selected high-risk patients who also receive reinforced VRD in settings where CD38 inhibitors are unavailable.”
• Host summary [08:10]:
  “There isn’t a universal microenvironment supporting all malignant plasma cell clones. Rather, there are multiple niche environments that vary by patient and across the three-dimensional marrow architecture.”
• Leo Raske & Niels Weinhold [08:44]:
  “This architecture is only one feature of the intra- and inter-patient variability that must be understood to advance our understanding of multiple myeloma.”

Timestamps for Key Segments

| Timestamp | Topic | |-----------|--------------------------------------------------------------------------------------------------| | 00:32 | Introduction to busulfan-melphalan vs. melphalan conditioning, rationale for the study | | 01:06 | Study design, inclusion criteria, and trial arms (GEM12, reinforced VRD induction) | | 02:26 | Primary and secondary outcomes, subgroup and safety findings | | 03:30 | Commentary and clinical implications (Donna Reese) | | 04:16 | Introduction to spatial transcriptomics in multiple myeloma | | 04:47 | Methods: sample selection, preservation innovations, spatial profiling approach | | 05:18 | Key findings on cell type proportions and plasma cell diversity | | 06:16 | Description of spatial plasma cell patterns, examples of genotype-environment correlation | | 07:30 | Stromal microenvironment findings and unique “niche” concept | | 08:27 | Expert commentary (Leo Raske and Niels Weinhold), summary of clinical and research impact |

Conclusion

This episode highlights two pivotal advances in multiple myeloma research:

• BUMEL conditioning offers no overall survival advantage over MEL200 for most, but may especially benefit high-risk patients, particularly in settings without access to CD38 inhibitors.
• Spatial transcriptomics uncovers remarkable three-dimensional heterogeneity in myeloma bone marrow, revealing patient-specific plasma cell subtypes and microenvironments and challenging the notion of a uniform tumor-supportive niche.

For more details and full articles, visit bloodjournal.org.